Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Maryna C. Eichelberger
Office of Vaccine Research and Review, Center for Biologics Evaluation and Research,
FDA, Bethesda
Tanzania
Research Article
Qualitative Differences in T cell responses to Live, Attenuated and Inactivated Influenza Vaccines
Author(s): Maryna C. Eichelberger, Katie H. Rivers, Rebecca Ream, Jin Gao, Arash Hassantoufighi, Matthew R. Sandbulte and Timothy M. StraightMaryna C. Eichelberger, Katie H. Rivers, Rebecca Ream, Jin Gao, Arash Hassantoufighi, Matthew R. Sandbulte and Timothy M. Straight
Annual epidemics of influenza cause considerable morbidity and mortality. Trivalent inactivated vaccine (TIV) and live, attenuated influenza vaccine (LAIV) are licensed in the United States, and both are effective in preventing disease in persons younger than 49. Serum hemagglutination inhibition (HI) titers correlate with TIV but not LAIV efficacy, suggesting that additional effector mechanisms are induced to the live, attenuated vaccine and play an important role in protection against disease. For this reason there is a need to identify surrogate markers of LAIV efficacy that are easily measured in robust assays. We have compared the immunogenicity of TIV and LAIV in a small clinical study (16 age-matched volunteers in each vaccine group) by measuring serologic responses using traditional HI and NA inhibition assays as well as a sensitive cell-based neutralization assay. In addition.. View More»
DOI:
10.4172/2155-9899.S4-002